SCIENTIFIC EVIDENCE

SH3GL1-activated FTH1 inhibits ferroptosis and confers doxorubicin resistance in diffuse large B-cell lymphoma.

Clinical and translational medicine

Duan ZW, Wang WT, Wang Y, Wang R, Hua W, Shang CY, Gao R, Shen HR, Li Y, Wu JZ, Yin H, Wang L, Li JY, Xu W, Liang JH.

Publication Overview

Key findings, Countstar context, and access to the original paper.

2025

Cancer Research

Immunology

No items found.

Key Finding

These findings emphasise SH3GL1 as a promising prognostic biomarker and a potential therapeutic target in DLBCL, offering new avenues for treatment strategies aimed at overcoming drug resistance and improving patients' outcomes.

Countstar Connection

Countstar (model not specified) was used for cell numbers measurement in the study's cell samples during growth assessment for the cancer-model experiments.

Stay Connected to

Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.

Meet us online